Cytheris closes EUR 24.3M Series B financing
Funds to progress Phase II clinical studies of IL-7 to treat HIV
Leading the round was CDC Entreprises Innovation (France), with the remaining investors being AXA Private Equity (France), BIOAM/Bioamgestion (France), Crédit Agricole Private Equity (France), T2C2/Bio 2000 (Canada) and Caisse de Dépôt et Placement du Québec (CDPQ) (Canada) also participated.
Cytheris is focusing the development of IL-7 on selected projects with high probability of success and blockbuster potential. According to Cytheris, more than 50 patients treated in various proof of concept studies in US and France confirm IL-7 excellent clinical tolerance and impressive activity. Most active or passive immunotherapies for life threatening diseases will need the support of IL-7 to make a large number of T lymphocytes available for therapeutic responses, according to the company.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.